AC Immune SA
Biopharmaceutical company developing therapies for neurodegenerative diseases, including therapeutic vaccines for Alzheimer's disease.
Price history of AC Immune SA
Price history of AC Immune SA
Performance & Momentum
Strategic Analysis
AC Immune SA • 2026
AC Immune SA is a biotech company specialized in neurodegenerative diseases, with a differentiated approach based on immunotherapy and targeted diagnostics. Its positioning relies on highly scientific niche expertise tied to complex conditions where unmet medical needs remain significant and where the potential value depends heavily on clinical progress.
- Clear positioning in a segment with high unmet medical need
- Recognized expertise in immunotherapy and biomarkers for neurodegenerative diseases
- High potential for value creation in the event of clinical or strategic partnership success
- Significant dependence on clinical trial outcomes and regulatory approval
- Structurally limited financial visibility, with high sensitivity to funding
Momentum appears favorable and sustained, with a marked improvement over the past year. Despite a still-fragile long-term track record, the stock is showing renewed interest, suggesting a market repositioning toward the optionality value of its clinical pipeline; for an investor, this remains a speculative exposure with high execution leverage.
Similar stocks to AC Immune SA
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
